The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors.
 
Soohyeon Lee
Stock and Other Ownership Interests - Celgene/Bristol-Myers Squibb; Pfizer
Consulting or Advisory Role - PharmAbcine
Research Funding - Jeil Pharmaceutical Co
Travel, Accommodations, Expenses - ST Cube
 
Sangjoon Shin
No Relationships to Disclose
 
Patricia LoRusso
Stock and Other Ownership Interests - BAKX Therapeutics
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; BAKX Therapeutics; Bayer; Black Diamond Therapeutics; Compass Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImCheck therapeutics; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Mekanistic Therapeutics; Molecular Templates; Molecular Templates; Neurotrials Research; Pfizer; QED Therapeutics; Qualigen Therapeutics; Relay Therapeutics; Roche/Genentech; Roivant; Salarius Pharmaceuticals; Scenic Biotech; Seagen; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Stemline Therapeutics; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Christian Diego Rolfo
Leadership - ELSEVIER; ESMO; European School Oncology; IASLC; International Society of Liquid Biopsy
Consulting or Advisory Role - Amgen; Archer; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Pharmaceuticals; BostonGene; Bristol-Myers Squibb; Clinical Education Alliance; Cor2Ed; Daiichi Sankyo Europe GmbH; Diverse Health Hub; Eisai; EMD Serono; EMD Serono; General Dynamics Information Technology (GDIT); Genzyme; Guardant Health; Inivata; Intellisphere; Janssen Scientific Affairs; LUNGEVITY; MedStar Health; Merck Serono; Mirati Therapeutics; MJH Live Events; Novartis; ONCLIVE; Physicans' Education Resource; Physicans' Education Resource; Regeneron; ROCHE
Speakers' Bureau - AstraZeneca; Guardant Health; MSD; Roche Molecular Diagnostics
Research Funding - Lung Cancer Research Foundation
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Guardant Health
 
Hyunjin Jung
Leadership - ST Cube
Stock and Other Ownership Interests - ST Cube
 
Stephen Sunghan Yoo
Employment - STCube Pharmaceuticals Inc.
Stock and Other Ownership Interests - ST Cube; ST Cube (I)
Patents, Royalties, Other Intellectual Property - ST Cube
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Infinity Pharmaceuticals; Janssen; Liberum; MedaCorp; Medscape; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer; Telperian